Agrochemical and biotech giant Bayer has agreed to pay $7.25 billion dollars to settle claims that its Roundup weedkiller causes non-Hodgkin lymphoma, a form of blood cancer.
A Missouri judge Timothy Boyer approved the settlement on Nov. 20, determining it was, “fair, reasonable and adequate,” the BBC reported.
The settlement will be paid to Roundup users who are already sick with non-Hodgkin lymphoma and those who become ill in the future. Bayer will make annual payments into a fund over the next 21 years that will add up to the settlement amount.
Thanks for subscribing!
The money news that actually matters.
By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.
Payments to sick individuals will range from $10,000 to $165,000, depending on the severity of the cancer, when they were diagnosed and how often they used Roundup.
“Today’s final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice,” said Christopher Seeger, an attorney representing plaintiffs in the case, in a statement.
Bayer CEO Bill Anderson also called the settlement a “decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”
Bayer’s history of Roundup cases
The approved settlement all but ends a years-long legal battle in the U.S. for Bayer, which has paid $10 billion to resolve more than 100,000 cases related to Roundup in the past.
The court-approved $7.25 billion figure to potentially resolve remaining and future cases was proposed by the company in February 2026. Some plaintiff attorneys had objected to the cash amount, claiming it was not enough. However, Boyer said he did not want to delay payouts to sick victims.
Roundup contains glyphosate, a herbicide that the International Agency for Research on Cancer, a department under the World Health Organization, called a probable human carcinogen in 2015. Both Bayer and the Environmental Protection Agency have disputed those findings.
Roundup was introduced by Monsanto in the 1970s, a company Bayer bought in 2018 for more than $60 billion. Since then, the company has faced thousands of lawsuits in state and federal courts.
Non-Hodgkin lymphoma starts in white blood cells called lymphocytes, which make up most of your lymph system — part of your immune system — that helps fight infections and other diseases. The cancer causes lymphocytes to grow abnormally and too quickly.
Must Read
- Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
- The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
What happens next?
Plaintiffs still have the option of appealing the ruling or opting out of the settlement. For these reasons, the latest legal ruling does not eliminate all ongoing cases or those that could be brought against the company in the future.
Bayer, however, said that it expects the vast majority of people to accept the deal.
“The company expects the number of opt outs to be manageable and amount to a very low percentage of current and potential future claims,” it said, adding that it is “adequately provisioned” to manage remaining litigation.
The ruling follows a June Supreme Court decision in favor of Bayer, which overturned a $1.25 million settlement for a Missouri man, John Durnell, who said Roundup and its active ingredient glyphosate was to blame for his non-Hodgkin lymphoma diagnosis.
The court ultimately said that Bayer cannot be sued in state courts over cancer warning labels because federal regulations do not require them.
“Any plaintiff who chooses to litigate will face the burdens of both establishing that they have viable claims post-Durnell and ultimately proving them to a judge and jury,” the company said on Nov. 20.
You May Also Like
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and 3 simple steps to fix it ASAP
- A single line on your car insurance policy could be inflating your premium by up to 30% — here's what to change
Danni Santana is a journalist based out of New York City with a decade of experience reporting and editing business stories about retail, restaurants, sports, and personal finance.
